OCGN
Ocugen IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$409.61M
P/E Ratio
—
EPS
$-0.24
Beta
2.21
52W High
$2.73
52W Low
$0.90
50-Day MA
$1.55
200-Day MA
$1.53
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
13.07
PEG Ratio
—
About Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.
Fundamentals
| Revenue (TTM) | $4.46M |
| Gross Profit (TTM) | $-37.01M |
| EBITDA | $-63.87M |
| Operating Margin | -1164.00% |
| Return on Equity | -660.00% |
| Return on Assets | -68.20% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $-0.04 |
| Price-to-Book | 70.56 |
| Price-to-Sales (TTM) | 91.74 |
| EV/Revenue | 92.06 |
| EV/EBITDA | -1.95 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 3.50% |
| Shares Outstanding | $338.52M |
| Float | $316.86M |
| % Insiders | 1.68% |
| % Institutions | 34.09% |
Historical Volatility
HV 10-Day
52.88%
HV 20-Day
49.62%
HV 30-Day
77.23%
HV 60-Day
71.86%
HV Rank
54.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($11.43 target)
1
Strong Buy6
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026